Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Their cost of bitcoin mining is $4000
“On a per unit basis, the Company spends about $65 per miner per month, which is about equal to the current price of $4,000 per BTC. ”. More than profitable right now $$$$
Next quarterly report will be great!!
HUT8mining and MARA
MGTI Will be $3-5/share when bitcoin>$20k
And above $1/share when BTC is >$18k
Thumbs up longfellow
What do you think the odds are DCVAX-L will show positive P3 results?
Ps Point taken long fellow.
This will be worth a lot more than $10b.
I know it is Keytruda. It was a typing error. Assessing people on typing errors is a sign of weakness.
Page 9 https://d1io3yog0oux5.cloudfront.net/_b785840b5bd19c408c9e8db633fb660b/oncolyticsbiotech/db/300/2426/pdf/6.13.19+-+Corporate+Presentation.pdf
https://ir.oncosec.com/press-releases/detail/1998/ucsf-doses-first-patient-in-triple-combination-clinical
https://www.rexahn.com/product-pipeline For example RX-5902
https://www.leaptx.com
Already 4 examples of non-chemotherapeutic treatments using Keytruda in combination.
Looking to recent buyout Numbers in oncology >$20b is not too far fetched.
If you see other Cancer trials, there are a lot of them using a combination eg of Keytrada + a new treatment.
The fact that they want to use DCVAX in combination means that they are convinced of the efficacy of DCVAX alone.
If DCVax-L shows positive P3 results this also raises the chance that the company will be bought out by a big Pharma company. Considering the entire pipeline this should be higher than $20b.
Look at the LinkedIn profile of Mme Powers. She has more than 200 acknowledgements from the medical community, for example from the medical director oncology of GSK.
DCVax-L is nearing topline results (as is Multikine from CVM) both having the same market cap. If results of DCVAX-L are positive, which I expect, we will be talking about a game changer. And game changers have market caps of +$20b
Crossover results could be great as well if they can show that a significant higher percentage is still alive vs life expectancy on SOC (or SOC+other treatments) alone.
Ps No problem for your previous post.
Did anybody see Mme Powers’ LinkedIn profile and how many acknowledgments she gets from the medical community? DCVAX-L could be a game changer like Keytruda. Mme Powers knows what she is doing.
If that were the case the IDMC would have stopped the possibility of crossover during the trial because of lack of efficacy. But the oppositie happened: more patients than expected chose to crossover probably encouraged by their doctors who saw great crossover results.
If DCVAX-L would not have worked or if there was no statistical possibility that DCVAX-L worked the IDMC (interim data monitoring committee) would have stopped the trial because of lack of efficacy.
The fact that so many patients did chose to cross over to DCVax-L is also very positive. Doctors probably advised their patients to do the crossover because they saw good previous results on other unblinded crossover patients.
This will run to $.60 before the SAP is approved.
This will run to $.80 when we get a deadline when the topline results are approved
This will run to $5-8 on positive P3 results
This will run to $12-20 on FDA approval
If DCVAX-L would not have worked or if there was no statistical possibility that DCVAX-L worked the IDMC (interim data monitoring committee) would have stopped the trial because of lack of efficacy.
The fact that so many patients did chose to cross over to DCVax-L is also very positive. Doctors probably adviseur patients to do the crossover because they saw good previous results on the unblinded crossover patients.
Thank you. I am looking forward to the results. They could give a major breakthrough in cancer therapy.
Thank you. Followed by a buyout most probably for $7-10b
What is the price target if DCVAX-L shows positive results?
The SAP is needed due to the success of the cross-over possibility.
I cannot imagine the FDA could decline the plan, because they agreed with the study design to cross-over themself in the first place.
I think the P3 results will be brilliant. Looking for a $10-20b market cap once the brilliant results are in.
If DCVax-L works, and in compassionate use cases+P1/P2 cases we already see some exceptional results, MC could be $10-20B. Even with 1b fully diluted shares (now they have 650m shares fully diluted) that would mean $10-20/share.
Don’t forget the market gives DCVax-L a chance with a current MC of +$100m.
How much cash do they have? How long do they have before they are running out of cash?
At what share price?
If results are exceptional,the big 5 (GSK, Pfizer, BMS, AstraZeneca, Amgen) will line up to buyout NWBO or at least partner.
But can someone answer my questions please?
1. How many shares-fully diluted does the company have right now?
2. What’s their cash position?
3. What’s your price prediction on positive DCVax-L results?
Very long time ago. So, can you answer my questions?
I am new to this stock. What is the fully diluted number of outstanding shares (after warrant conversion, if any)?
What is the consensus price target if DCVax-L meets the primary endpoint, whether that is mOS (if SAP is not approved by the regulators) or the survival tail vs historic survival Numbers?
Thank you in advance.
DPW should be valued $.80/share at least. If they would sell Enertec now, they would get $35M.
Company’s revenues the last quarter were $6M, which is twice the current market cap.
$50M in assets.
Increase in institutional ownership reported on March 31 2019. Net increase was 1,400,000 shares. Shareholders are Goldman Sachs, Vanguard, Barclays, Ansom pension fund. There is also little insider buying.
Debt reduced, and BTC up big time. Net profitability is expected this quarter.
Great analysis!!!
Ok thank you
What are the price targets we are talking about here on positive P3 results, knowing that the fully diluted number of outstanding shares is 44-49 million.
While we wait, others are buying shares because the chances for a positive outcome are increasing.
If P3 results are bad,Ergomed will receive money by the sale of the manufacturing plant and domain.
The OS rate on SOC is 55% for newly diagnosed stage 3 and 4a head and neck cancers, which are the types that are included in the study.
Uptrend confirmed now. Let’s attack $4/share. Not selling before any buyout (I think it’ll be around $150/share)
During the latest presentation it was clearly stated that Keytruda or Opdivo have NOT been used in the P3 trial of Multikine!
Higher highs+higher lows.Uptrend,$4/sh soon. $50/share on positive P3 results and +$100/share on buyout
Happy at $14/share, retired at $100/share